![conference banner](/images/conference-banner.jpeg)
Abstract
Background: The brain is a well-protected organ, with a complex system of cells, proteins and transporters, that acts as a sentinel to prevent potentially harmful substances from entering the brain, stopping also active molecules administered with a therapeutic goal. Although their limited exploitation, dendrimers are currently under evaluation as drug vectors to improve pharmacological treatments, targeting active molecules across the blood-brain barrier and penetrating brain tissues.
Methods: Up to date, only three different families of dendrimers, poly(amidoamine)-, poly(propyleneimine)- and poly(L-lysine)-based, have found application as drug transporters in the Central Nervous System. Their development, functionalization and characterization are reported in the literature, with interesting preliminary outcomes in the treatment of brain disorders. Surface functionalization also affects the interaction between dendrimers and cells or tissues, with effects not only on penetration and retention, but also on the safety profile of this drug carrier. Conclusion: This review focuses on the application of dendrimers in the field of targeted drug delivery toward the Central Nervous System, highlighting their interesting properties. Discussion will be promising and represent an important starting point for a further diffusion of dendrimers in pharmacological treatment of the Central Nervous System.Keywords: Brain, CNS, dendrimer, drug delivery, drug targeting, PAMAM, PPI, PLL.
Current Pharmaceutical Design
Title:Recent Advances in Preclinical Studies and Potential Applications of Dendrimers as Drug Carriers in the Central Nervous System
Volume: 23 Issue: 21
Author(s): Mariacristina Gagliardi*
Affiliation:
- Multi-scale Analysis of Materials, IMT School for Advanced Studies Lucca, Lucca, Italy; Center for Micro- BioRobotics @SSSA, Istituto Italiano di Tecnologia, Pontedera,Italy
Keywords: Brain, CNS, dendrimer, drug delivery, drug targeting, PAMAM, PPI, PLL.
Abstract: Background: The brain is a well-protected organ, with a complex system of cells, proteins and transporters, that acts as a sentinel to prevent potentially harmful substances from entering the brain, stopping also active molecules administered with a therapeutic goal. Although their limited exploitation, dendrimers are currently under evaluation as drug vectors to improve pharmacological treatments, targeting active molecules across the blood-brain barrier and penetrating brain tissues.
Methods: Up to date, only three different families of dendrimers, poly(amidoamine)-, poly(propyleneimine)- and poly(L-lysine)-based, have found application as drug transporters in the Central Nervous System. Their development, functionalization and characterization are reported in the literature, with interesting preliminary outcomes in the treatment of brain disorders. Surface functionalization also affects the interaction between dendrimers and cells or tissues, with effects not only on penetration and retention, but also on the safety profile of this drug carrier. Conclusion: This review focuses on the application of dendrimers in the field of targeted drug delivery toward the Central Nervous System, highlighting their interesting properties. Discussion will be promising and represent an important starting point for a further diffusion of dendrimers in pharmacological treatment of the Central Nervous System.Export Options
About this article
Cite this article as:
Gagliardi Mariacristina*, Recent Advances in Preclinical Studies and Potential Applications of Dendrimers as Drug Carriers in the Central Nervous System, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170313124811
DOI https://dx.doi.org/10.2174/1381612823666170313124811 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-coding RNAs as Biomarkers for Survival in Colorectal Cancer Patients
Current Aging Science The Pharmacological Treatment of Cachexia
Current Drug Targets Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Antioxidant Hybrid Compounds: A Promising Therapeutic Intervention in Oxidative Stress Induced Diseases
Mini-Reviews in Medicinal Chemistry Visualization of DNA Double-Strand Break Repair: From Molecules to Cells
Current Medical Imaging Regulation of the Metabolism of Polyunsaturated Fatty Acids and Butyrate in Colon Cancer Cells
Current Pharmaceutical Biotechnology A Novel Fluorescence-Labeled Curcumin Conjugate: Synthesis, Evaluation and Imaging on Human Cell Lines
Current Pharmaceutical Design IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Current Medicinal Chemistry Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review
CNS & Neurological Disorders - Drug Targets Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Nanoformulations of Plant-Derived Compounds as Emerging Therapeutic Approach for Colorectal Cancer
Current Drug Delivery Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued)